

## Oral Vaccination- PerOs and Benchmark say Yes!

Montreal, Quebec, May 2nd, 2007 - Oral administration of vaccines and other bioactive substances for livestock industries is by far the most sought after method of delivery. Oral vaccine delivery requires no disruption in normal animal husbandry or additional handling; thus, eliminating the stress and cost associated with other methods of administration. Oral vaccination is the only method suitable for the rapid and simultaneous mass immunization of bioactive compounds to a large population; which is essential for the prevention and control of disease outbreaks.

PerOs Systems Technologies Inc, an emerging biotechnology company that has developed a unique and proprietary oral drug delivery platform - Oralject™ and Benchmark Biolabs Inc, a US-based biopharmaceutical product development firm focused on the validation, development, optimization and commercialization of biologics- "from concept to commercialization," have teamed up to make oral vaccination a reality and the rapidly growing aquaculture industry is the first commercial target.

Benchmark's proven track record over its ten year history, such as co-developing the worlds first plant-derived vaccine approved by the USDA, including the design, licensure, and management of the associated manufacturing facility, make them the perfect partner to complete the development effort for PerOs and design and manage a fully licensed facility to incorporate the desired bioactive components into the Oralject platform.

The core of Benchmark's business over the last decade has been to apply creative science to support regulatory approval for both conventional and innovative product development. Benchmark's customer base represents a broad composite of firms seeking to develop or manufacture best-in-class products in the biological sector.

PerOs will focus the initial commercial effort of its Oralject technology to meet the demands of the rapidly growing aquaculture industry. The intensification of fish farming has resulted in an increased need to control disease to decrease sickness and improve growth performance. Much effort has been dedicated to vaccine development and the use of vaccines has become an essential component of disease management in fish farming.

Oralject offers a number of powerful advantages over current therapies. Oralject does not require any specialists or specific skills as delivery consists of a single meal being simply replaced with Oralject. With no needles and a simple administration procedure, Oralject technology provides a straightforward, cost-effective solution that requires only minimal human intervention, leading to important labor savings thus is ideal for rapid mass vaccination of large populations of animals.

Benchmark's proven team of product development scientists and manufacturing specialists plans to enable of a broad spectrum of bioactive compounds and expand the scope of Oralject applications. Benchmark Biolabs has already completed the construction of an Oralject manufacturing facility on its campus in Lincoln, Nebraska and plans to complete the licensed facility for the final phase of manufacturing by the fall of 2007.

PerOs' plans to sell and supply its proprietary Oralject delivery system to regional and multinational pharmaceutical companies, veterinary service organizations and certain fully integrated producers that manufacture custom vaccines for their own use.

For more information on Benchmark Biolabs: [www.benchmarkbiolabs.com](http://www.benchmarkbiolabs.com)

For more information  
Jean-Simon Venne  
Business Development  
PerOs Systems Technologies Inc.  
Phone: 1 (514) 848.6421  
Email: [jsvenne@perosbio.com](mailto:jsvenne@perosbio.com)